FDA approved AstraZeneca’s Klygefa, a weekly self injected C5 inhibitor for AChR positive myasthenia gravis. What PREVAIL showed and what is still unknown.
Last updated: November 16, 2026
The FDA has approved Klygefa (gefurulimab) from Alexion, AstraZeneca Rare Disease, for adults with generalized myasthenia gravis who are AChR antibody positive. It is a C5 complement inhibitor patients inject themselves once a week, backed by the 260 patient Phase III PREVAIL trial.
Scope: what was approved, what the trial showed, how Klygefa sits against the other C5 drugs in myasthenia gravis, and what AstraZeneca has not yet disclosed.
What did the FDA approve?
AstraZeneca announced on November 16, 2026 that the FDA approved Klygefa (gefurulimab) for generalized myasthenia gravis (gMG) in adults who are anti acetylcholine receptor (AChR) antibody positive. The company calls it the first and only dual binding nanobody C5 inhibitor in the US, and it is given as a once weekly subcutaneous injection that patients give themselves with an autoinjector.
That last detail is the commercial story. Complement C5 inhibition is a proven mechanism in gMG, and Alexion already sells two intravenous C5 antibodies. What Klygefa changes is the delivery: a home injection once a week instead of an infusion chair or a daily shot. Dosing starts with a single weight based loading dose on Day 1, then weight based maintenance from Day 8 and weekly after that, according to the company.
The Muscular Dystrophy Association put out its own statement the same morning welcoming the approval and noting that Alexion plans an industry webinar on December 8, 2026.
What did the PREVAIL Phase III trial show?
PREVAIL met its primary endpoint: on the MG ADL scale (the Myasthenia Gravis Activities of Daily Living score, where lower is better), gefurulimab improved scores by 1.6 points more than placebo at week 26 (treatment difference −1.6, 95% CI −2.4 to −0.8, p<0.0001). Improvement showed up as early as week one, the company says.
The trial details from AstraZeneca’s release:
| PREVAIL item | Detail |
|---|---|
| Design | Global Phase III, randomized 1:1, double blind, placebo controlled (ALXN1720-MG-301, NCT05556096) |
| Patients | 260 adults from 20 countries across North America, Europe, Asia and the Pacific |
| Controlled period | 26 weeks |
| Primary endpoint | Change from baseline in MG ADL total score at week 26 |
| Result | Treatment difference −1.6 points (95% CI −2.4 to −0.8), p<0.0001 |
| Onset | Clinical improvement observed as early as week one |
| Most common adverse events | Injection site reactions 12%, back pain 8%, vomiting 5%; most events grade 1 or 2 |
| Publication | JAMA Neurology (Gwathmey KG et al., July 27, 2026) |
AstraZeneca says the safety profile was consistent with Alexion’s intravenous C5 antibodies eculizumab (Soliris) and ravulizumab (Ultomiris), and that the share of patients with treatment emergent adverse events was similar to placebo.
How does Klygefa compare with Ultomiris and Zilbrysq?
All three are C5 inhibitors labeled for AChR antibody positive adults, so the practical difference is how often and where the drug is given. Klygefa is weekly and self injected, Ultomiris is an infusion every eight weeks, and UCB’s Zilbrysq (zilucoplan) is a daily self injection.
| Drug (company) | Molecule type | Route and schedule | Pivotal trial | Primary result (MG ADL vs placebo) |
|---|---|---|---|---|
| Klygefa, gefurulimab (Alexion, AstraZeneca) | Dual binding nanobody | Subcutaneous autoinjector, once weekly after a Day 1 loading dose | PREVAIL, n=260 | −1.6 at week 26 (95% CI −2.4 to −0.8) |
| Ultomiris, ravulizumab (Alexion, AstraZeneca) | Monoclonal antibody | Intravenous, every eight weeks after a loading dose | CHAMPION-MG, n=175 | Superior to placebo at week 26 (company release gave no number) |
| Zilbrysq, zilucoplan (UCB) | Peptide | Subcutaneous, once daily, weight based | RAISE, n=174 | −2.09 at week 12 (95% CI −3.24 to −0.95) |
Do not read the effect sizes across rows as a ranking. The trials measured at different weeks (12 versus 26), enrolled different populations and ran at different times. Head to head data do not exist.
Ultomiris was approved for gMG on April 28, 2022, per AstraZeneca’s filing that day. Zilbrysq was approved in October 2023; its label carries a boxed warning for serious meningococcal infections and requires a REMS program with prescriber enrollment and certified pharmacies.
Does Klygefa carry a meningococcal boxed warning?
AstraZeneca’s approval release does not say. It contains no safety information section and no mention of a boxed warning, REMS or vaccination requirement. That matters because blocking C5 raises the risk of meningococcal infection, and Zilbrysq’s label states that life threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors.
Our read: prescribers and payers should assume class style vaccination and monitoring requirements until the Klygefa prescribing information is posted, then check the label itself. We will update this article when it is.
Why does this approval matter for the gMG market?
It shifts competition in AChR positive gMG from mechanism to convenience. The approved C5 options until now forced a trade between infusion visits (Ultomiris) and daily injections (Zilbrysq). A weekly home injection sits between them, and for Alexion it is a way to keep patients inside its own C5 franchise as more self administered options reach the market.
The patient pool is meaningful. AstraZeneca estimates about 98,500 people in the US are diagnosed with gMG, of whom 81,000 are AChR antibody positive, the group this label covers.
For operators, the autoinjector moves the product from the infusion center channel toward specialty pharmacy. That changes who handles distribution, patient training and any REMS style controls, and it changes how payers will manage the drug under pharmacy versus medical benefits. AstraZeneca has not said how it will price or distribute Klygefa.
Where else is Klygefa approved?
AstraZeneca says Klygefa is approved in the European Union, Japan and other countries for certain adults with gMG, with filings under review in China and elsewhere. The EU step came after a positive CHMP opinion on September 21, 2026, which recommended it as an add on to standard therapy in AChR antibody positive adults, per AstraZeneca’s SEC filing that day.
What is still unknown?
- Price: not disclosed.
- Launch timing: the release says only that Alexion looks forward to delivering it soon.
- Label warnings: boxed warning, REMS and vaccination language not stated in the release.
- Dose amounts: weight based schedule described, milligram amounts not given.
- Payer coverage: no formulary positions announced.
Checklist: how to evaluate Klygefa for your formulary or practice (our framework)
- Pull the full prescribing information and confirm boxed warning, REMS and vaccination timing before the first order.
- Confirm AChR antibody status; the US label covers AChR antibody positive adults only.
- Map current C5 patients by burden: infusion visits on Ultomiris versus daily injections on Zilbrysq.
- Decide the benefit channel (pharmacy versus medical) and the specialty pharmacy route once AstraZeneca discloses distribution.
- Compare price per year against current C5 and non C5 options once list price is public.
- Set a switching protocol, including the Day 1 loading dose and weekly maintenance from Day 8.
- Plan patient injection training and adverse event follow up for injection site reactions.
What to watch next
- Posting of the Klygefa prescribing information on FDA’s database, and whether it matches Zilbrysq’s boxed warning and REMS structure.
- List price and launch date from Alexion.
- Alexion’s December 8, 2026 industry webinar, flagged in the MDA statement.
- China and other pending reviews.
- Payer coverage decisions in early 2027.
FAQ
What is Klygefa?
Klygefa (gefurulimab) is a C5 complement inhibitor from Alexion, AstraZeneca Rare Disease. AstraZeneca describes it as a dual binding nanobody, and it is given by weekly subcutaneous self injection with an autoinjector.
When was Klygefa approved by the FDA?
AstraZeneca announced the US approval on November 16, 2026. The release does not state the exact FDA action date.
Who is Klygefa approved for?
Adults with generalized myasthenia gravis who are anti acetylcholine receptor (AChR) antibody positive.
How often is Klygefa given?
Once a week after a weight based loading dose on Day 1, with weight based maintenance dosing starting on Day 8.
How well did Klygefa work in PREVAIL?
It improved the MG ADL score by 1.6 points more than placebo at week 26 (95% CI −2.4 to −0.8, p<0.0001) in 260 patients, with improvement seen from week one.
What were the most common side effects?
Injection site reactions (12%), back pain (8%) and vomiting (5%), mostly grade 1 or 2, according to AstraZeneca.
Is Klygefa better than Zilbrysq or Ultomiris?
There is no head to head trial. The pivotal trials measured outcomes at different time points in different populations, so cross trial comparisons of effect size are not reliable.
Does Klygefa require meningococcal vaccination?
AstraZeneca’s release does not say. Other C5 inhibitors such as Zilbrysq carry a boxed warning and REMS for meningococcal infections, so check the Klygefa label once posted.
How much does Klygefa cost?
AstraZeneca has not disclosed a price.
Is Klygefa approved outside the US?
Yes. AstraZeneca says it is approved in the EU, Japan and other countries, with reviews ongoing in China and elsewhere.
Sources
- AstraZeneca, “Klygefa (gefurulimab) approved in the US for the treatment of generalised myasthenia gravis (gMG) in adult patients,” November 16, 2026 (primary).
- AstraZeneca Form 6-K, CHMP positive opinion for Klygefa, September 21, 2026, SEC EDGAR (primary).
- AstraZeneca Form 6-K, Ultomiris US approval in gMG, April 28, 2022, SEC EDGAR (primary).
- Zilbrysq (zilucoplan) US prescribing information, revised October 2023, FDA (primary).
- Muscular Dystrophy Association statement on Klygefa approval, GlobeNewswire, November 16, 2026 (attributed).
- Practical Neurology, Zilbrysq approval report, October 19, 2023 (attributed, approval timing).
Related coverage
- Boxed Warning vs Warnings and Precautions: How FDA Flags Risk
- Subcutaneous vs IV Biologics: How Hyaluronidase Changes Dosing
- PDUFA Date Explained: Goal Dates, Extensions and FDA Decisions
- Sunharbo Approval: First Factor XIa Drug Cuts Strokes 26%
- Pimjetmi Approved as First Once Daily CSF1R Drug for TGCT
- BioMed Nexus company directory
Get the daily briefing: subscribe to BioMed Nexus.


